Three major studies found finerenone protects kidneys and hearts in millions with non-diabetic kidney disease too.
A kidney medication called finerenone, previously approved only for diabetics, reduced death risk by 12% across 14,574 patients with all types of chronic kidney disease. The drug also cut kidney failure risk by 24% and heart complications by 20%. Most importantly, these benefits appeared whether patients had diabetes or not—expanding potential treatment to millions more people.
This matters because most people with chronic kidney disease don't actually have diabetes, yet they've had limited treatment options until now. The drug works by blocking mineralocorticoid receptors that drive inflammation and scarring in kidneys. The main side effect was elevated potassium levels, but serious complications from this were rare and most patients stayed on the medication.
Chronic kidney disease affects 850 million people worldwide and is projected to become the fifth leading cause of premature death by 2040. Early intervention matters because as kidney function declines, risks for hospitalization, heart problems, and death increase sharply. These results suggest effective treatment may now be available for a much broader population.
What You Can Actually Do Today
- Ask your doctor to check your kidney function with a simple blood test measuring creatinine and estimated GFR if you haven't had one in the past year
- If you have kidney disease, discuss with your doctor whether finerenone might be appropriate given these new findings about non-diabetic patients
- Monitor your blood pressure consistently if you have kidney disease, as this drug may help with cardiovascular protection beyond kidney benefits
This medication requires prescription and monitoring. Discuss potential benefits and risks with your healthcare provider.
